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sive disease of the carotid bifurcation, when the surgical
procedure has been used rather effectively. Golledge et al4
recently reported an analysis of multiple series that identi-
fied the inferiority of carotid angioplasty when compared
with endarterectomy. In addition, recent multicenter
prospective randomized trial results of carotid stenting
versus endarterectomy showed a stroke and death rate of
12.1% at 1 year for stenting and a stroke and death rate of
3.6% for CEA.5 On the basis of a futility analysis, this clin-
ical trial was terminated after 219 of the planned 700
patients were enrolled.5
Because many studies have shown an inferiority of
carotid stenting for routine carotid revascularization,4-8
subsequent studies have sought the identification of cer-
tain subset patient populations that may be more appro-
priate for stenting. Occasionally, patients are considered to
be at high risk for surgical procedures and are not offered
CEA. These patients then undergo treatment with medical
therapy, including antiplatelet medication and control of
other risk factors, including hypertension, hyperlipidemia,
and smoking. Surprisingly, some clinicians have advocated
the use of stenting to avoid general anesthesia. However,
CEA can be performed with local or regional anesthesia
with similarly low stroke rates.9,10
Carotid endarterectomy (CEA) has been well-
established as an effective means for the reduction of
stroke for symptomatic and asymptomatic carotid steno-
sis.1,2 With technologic advances, there have been addi-
tional innovative approaches to the treatment of carotid
artery stenosis. Specifically, percutaneous transluminal
angioplasty and stenting has been explored as an alterna-
tive for CEA in some patients. Initial report results
showed a stroke rate of 9.7%,3 but because this technique
has been modified and improved during the last several
years, stroke rates may be reduced. However, the efficacy
of this technique remains uncertain, especially for occlu-
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Background: Carotid angioplasty and stenting is under investigation in clinical trials as an alternative to endarterectomy.
Some clinicians have hypothesized that stenting would be applicable for patients at high risk who need carotid revas-
cularization. To further test this hypothesis, we stratified our carotid endarterectomy procedures according to current
carotid stent protocols.
Methods: We reviewed our computerized registry and the clinical charts of patients who underwent carotid endarterec-
tomy. Each procedure was categorized as high risk or low risk, according to the following six separate high-risk fac-
tors: 1, severe cardiac dysfunction; 2, the requirement for combined coronary and carotid vascularization; 3, severe
pulmonary dysfunction; 4, contralateral internal carotid artery occlusion; 5, previous ipsilateral carotid endarterec-
tomy; and 6, anatomically limited access for carotid endarterectomy. Rates of stroke at 30 days, cardiac complications,
and death were tabulated.
Results: Between January 1, 1998, and December 31, 2000, 415 carotid endarterectomies were performed on 389
patients. Ninety-eight procedures (23.6%) were classified as high risk on the basis of the following factors: 1, severe car-
diac dysfunction (n = 30); 2, requirement for combined coronary and carotid revascularization (n = 14); 3, severe pul-
monary dysfunction (n = 8); 4, contralateral carotid occlusion (n = 31); 5, previous ipsilateral carotid endarterectomy
(n = 25); and 6, anatomically limited access (n = 4). Seven patients had ipsilateral postoperative strokes (1.7%), with two
additional patients having contralateral hemispheric strokes. One patient died from exacerbation of congestive heart fail-
ure 9 days after undergoing a second carotid endarterectomy. The total stroke and death rate was 2.6% for all the
patients. Two of the 98 procedures in the high-risk group were complicated with ipsilateral stroke (2.0%) as compared
with six of the 317 low-risk procedures (1.9%; P = 1). Six procedures were complicated with cardiac dysfunction after
surgery, including myocardial infarction, congestive heart failure, or the new onset of atrial fibrillation. Three cardiac
complications occurred in the low-risk group (1%), and three occurred in the high-risk group (3.1%; P = .15).
Conclusion: This series shows that patients at high risk can undergo carotid endarterectomy with stroke rates equiva-
lent to the rates of patients at low risk. The cardiac morbidity rate may be increased in the high-risk group. Carotid
stenting is unlikely to offer any improvement in stroke risk as compared with carotid endarterectomy, but stenting may
reduce non-stroke morbidity rates associated with some high-risk cases. (J Vasc Surg 2002;35:16-22.)
Carotid stenting protocols have been initiated for the
evaluation of a high-risk patient population on the basis of
certain physiologic and anatomic risk factors. Ouriel and
his colleagues11 have observed that certain medical risk
factors, including coronary, pulmonary, or renal disease,
are associated with a higher rate of stroke, death, or
myocardial infarction (MI) after CEA. In addition,
Rothwell, Slattery, and Warlow12 examined medical fac-
tors and found that female sex, systolic hypertension, and
the presence of peripheral vascular disease were associated
with a higher risk of stroke and death. They also identified
the following anatomic criteria that were associated with a
higher risk of stroke and death: contralateral carotid artery
occlusion, ipsilateral internal carotid siphon stenosis, or
ipsilateral external carotid artery stenosis. Some of these
criteria have been implemented in trials that evaluated
carotid stenting in patients at high risk. We then sought to
evaluate the impact of these factors on stroke risk, mor-
bidity, and mortality rates in a population of patients who
underwent CEA.
METHODS
During a 3-year period from January 1, 1998, to
December 31, 2000, 415 consecutive CEAs were per-
formed on 389 patients by five different surgeons at the
University of Alabama at Birmingham and the
Birmingham Veteran’s Affairs Medical Center.
Consecutive operations were prospectively entered into a
computerized registry, which included end points of
stroke, death, and MI. In addition, risk factors, including
the presence of coronary disease, hypertension, smoking,
chronic lung disease, obesity, and diabetes, were tracked
prospectively. We then retrospectively applied the follow-
ing risk factors for the classification of each procedure as
high risk or low risk. The high-risk factors included: 1,
severe cardiac dysfunction with a left ventricular ejection
fraction of less than 30% or a New York Heart Association
classification of 3 or 4 angina (severe cardiac dysfunction
was also defined as MI in the 4 weeks before surgery or
coronary bypass grafting operation in the 6 weeks before
surgery); 2, requirement for carotid and coronary or
major vascular procedure within 30 days of surgery; 3,
severe pulmonary dysfunction, defined as a forced expira-
tory volume in 1 second of less than 1.0 liters or the
requirement for home oxygen; 4, the presence of con-
tralateral carotid occlusion identified with carotid ultra-
sound scanning or angiography; 5, a previous ipsilateral
CEA; and 6, anatomically limited access, including a high
cervical internal carotid artery lesion or a common carotid
artery lesion below the level of the clavicle or a postradia-
tion treatment stenosis. Each procedure was categorized
as high risk or low risk on the basis of presence of at least
one of these criteria. Each patient could be classified in
more than one high-risk category. Primary end points
included death, stroke, or cardiac complications as defined
by the reporting standards of an ad hoc committee of the
Society of Vascular Surgery and the North American
Chapter of the International Society for Cardiovascular
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Surgery on cerebrovascular reporting.13 Strokes were
defined as the presence of a clinical neurologic deficit
beyond 24 hours. Cardiac complications were defined as
cardiac enzyme evidence of myocardial necrosis, an exac-
erbation of congestive heart failure that required addi-
tional hospitalization, or the new onset of atrial
fibrillation. Transient ischemic attack, neurologic deficit
lasting less than 24 hours, medically controlled angina,
and cranial nerve injuries were not stratified as end points. 
The specifics of the surgical procedure were left to the
discretion of the operating surgeon, but the principles of
the operative technique can be summarized in the follow-
ing manner: the type of anesthesia was selected on the
basis of the preferences of the surgeons and patients.
Angiography was undertaken selectively when more
anatomic information was required to define the indica-
tions for revascularization and the best operative tech-
nique. Selective shunting was used on the basis of
neurologic changes with regional anesthesia, on the basis
of electroencephalographic changes with general anes-
thetic, or when judged clinically appropriate by the oper-
ating surgeon. Synthetic patches were almost always used,
with the rare exception determined by the operating sur-
geon. Completion studies were not routinely undertaken
in the operating room and were reserved for abnormal
anatomy or inadequate sounds with continuous wave
Doppler scanning. The patients were typically monitored
in the recovery room for 2 hours before transfer to a reg-
ular nursing unit specializing in vascular care. The inten-
sive care unit was not routinely used.
The relationships between factors that potentially
affected perioperative complications (stroke, cardiac mor-
bidity, or death) were described with the calculation of the
percent of patients with such events. Because the number
of adverse events was small, assumptions underlying the
traditional χ2 test were not met. Therefore, statistical sig-
nificance of differences between strata defined by the pre-
dictive factors was assessed with maximum likelihood ratio
tests provided through logistic regression modeling.
Logistic regression was also used to estimate the odds ratio
Table I. Patient characteristics for total population of
patients who underwent carotid endarterectomy
Patient characteristics No. of patients (n = 415)
Male 288 (69.4%)
White 390 (94.0%)
Tobacco use 322 (77.6%)
Hypertension 304 (73.3%)
Coronary artery disease 218 (52.5%)
Chronic lung disease 53 (12.8%)
Dialysis/renal transplant 8 (1.9%)
Diabetes 107 (25.8%)
Hyperlipidemia 183 (44.1%)
Symptomatic 180 (43.4%)
Prior stroke 41 (9.8%)
Transient ischemic attack 119 (28.7%)
Amaurosis fugax 20 (4.8%)
for postoperative events associated with a 10-year differ-
ence in age (the only factor measured on a continuous
scale). A P value of less than .05 was considered significant.
RESULTS
The patient characteristics are outlined in Table I. The
population was predominately white male, with a mean
age of 67 years (range, 41 to 92 years). Diagnostic con-
trast arteriography was undertaken before 238 procedures
(54.9%) according to the discretion of the operating sur-
geon and the quality of noninvasive, preoperative imaging
results.
Strokes. Seven procedures were complicated with
postoperative ipsilateral strokes, and two additional proce-
dures were complicated with contralateral hemispheric
strokes that occurred from 7 to 19 days after the original
CEA. One of these contralateral strokes occurred after a
mitral valve replacement was undertaken for severe asymp-
tomatic stenosis after the CEA. The second contralateral
stroke occurred 19 days after a right CEA for 90% steno-
sis in a patient with bilateral visual disturbances. The
patient underwent an uneventful left CEA for the 70%
stenotic lesion 6 weeks after the stroke and had only minor
hand numbness 30 days after the second operation. In
addition, one patient died 9 days after the second CEA.
Both of the CEAs required additional hospitalization for
exacerbation of congestive heart failure. However, the
patient died a sudden death at home after congestive heart
failure had compensated. The total stroke and death rate
was 2.4% after all procedures and 2.6% for all patients.
Seven other patients (two in the high-risk group and
five in the low-risk group) had postoperative ipsilateral
strokes that ranged from 0 to 9 days after the surgical pro-
cedures. Two major strokes (0.5%) occurred immediately
after surgery, one related to middle cerebral artery
embolization and the other to a low-flow state infarction
in a patient with multisite intracranial disease despite the
use of a shunt during the CEA. Five minor strokes (1.2%)
occurred after surgery, including two that were related to
reperfusion syndrome and two that were presumably
related to minor embolization that could not be identified
on radiographic study. The last minor stroke occurred 9
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days after the original CEA when angiography was under-
taken for the characterization of a false-positive defect
found on a magnetic resonance image. Twelve patients
(2.9%) were identified with cranial nerve deficits after the
procedure, 11 of which involved the marginal mandibular
nerve. All of the patients, except the one with a hypoglos-
sal nerve injury, recovered completely within 30 days.
High-risk procedures. Ninety-eight of the 415
CEAs (23.6%) were classified as high-risk procedures.
Specifically, contralateral occlusion, cardiac dysfunction,
and recurrent carotid stenosis were the most common
classifications for high-risk procedures (Table II). Only 14
patients underwent carotid and either cardiac or aortic
procedures within 30 days. Of the 14 patients who had
more than one risk factor, none had strokes or cardiac
morbidity. Forty of these 98 procedures (40.8%) were
undertaken for symptomatic stenosis (nine for stroke, 27
for transient ischemic attack [TIA], and four for amauro-
sis fugax), which was similar to the entire population of
415 procedures (Table I). 
Stroke rates in patients at high risk. In an evalua-
tion of all of the high-risk procedures (n = 98), 4.1% of the
patients had either stroke or death as compared with 1.9%
of the patients in the low-risk group. None of the six risk
factors could be identified as a significant predictor for
stroke or death after CEA (Table III). However, in a con-
sideration of cardiac morbidity in addition to stroke or
death, the patients at high risk had a total stroke, death, or
cardiac outcome rate of 7.1% versus a 2.8% rate in the low-
risk group (P = .07). This cardiac morbidity rate difference
was most dramatically seen in the cardiac dysfunction risk
group (10.0% versus 0.8%; P = .004). Of note, only one
patient in the high-risk cardiac group died and only three
other patients had cardiac morbidity develop (two patients
had MIs and one had an exacerbation of congestive heart
failure). There was no significant difference in stroke rate
between those patients who had contralateral carotid
occlusion or recurrent carotid stenosis. No patients with
recurrent carotid stenosis had a postoperative stroke,
death, or cardiac complication.
Additional risk factors. Further risk factor analysis
results provided additional information regarding stroke
Table II. Classification of each high-risk procedure on the basis of six criteria
No. of procedures Patients with more than one risk factor No. of procedures
Risk factors (n = 415) (of six factors listed in left column) (n = 14)
Cardiac dysfunction 30 (7.2%) Cardiac and combined revascularization 3
Combined coronary and 14 (3.3%) Contralateral occlusion and recurrent stenosis 3
carotid revascularization
Pulmonary dysfunction 8 (1.9%) Cardiac and contralateral occlusion 3
Contralateral occlusion 31 (7.5%) Cardiac and pulmonary dysfunction 1
Recurrent carotid stenosis 25 (6.0%) Cardiac and recurrent stenosis 1
Anatomically limited access 4 (1.0%) Combined revascularization and recurrent stenosis 1
Total risk factors 112 (NA) Radiation and contralateral occlusion 1
Total high-risk procedures 98 (23.6%) Combined revascularization and contralateral occlusion 1
Fourteen procedures (right column) were classified as high risk on the basis of more than one of six criteria.
and cardiac morbidity rates (Table IV). Female patients
had both a higher stroke rate and a higher combined mor-
bidity of stroke, death, or cardiac complication rate.
Patients who were asymptomatic had a lower stroke rate
(1.3%) as compared with patients who were symptomatic
(3.9%; P = .09). In addition, the presence of coronary
artery disease was associated with higher cardiac morbid-
ity rate but did not adversely impact stroke rate.
Furthermore, patients with diabetes had a higher stroke
rate (5.6%) when compared with patients without diabetes
(1.3%; P = .008). Also, a nearly equal number of proce-
dures were accomplished with general anesthesia versus
regional anesthesia. The stroke rate for general anesthesia
procedures (2.3%) was similar to the rate of procedures
accomplished with regional anesthesia (2.5%). However,
the cardiac morbidity rate was 1% in the regional group
and 1.9% in the general anesthesia group (P = .45). Age
did not have a significant impact on stroke or cardiac mor-
bidity.
DISCUSSION
After a period of careful scrutiny during the last 40
years, CEA has been shown to be a durable and effective
treatment for symptomatic and asymptomatic carotid
stenosis. Although most of the studies that established the
efficacy of this procedure have been undertaken in a care-
fully selected population, the general medical consensus
has applied the lessons learned from these studies to the
general population. Subsequently, we and many clinicians
around the country use CEA for a wide variety of patients.
The advocates of carotid stenting have suggested that
endarterectomy should not be so liberally applied outside
the patient at normal risk. Furthermore, because there
have been advancements in technologic capabilities in the
area of carotid angioplasty, these same advocates have pro-
moted the use of stenting for patients excluded from the
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North American Symptomatic Carotid Endarterectomy
Trial or Asymptomatic Carotid Atherosclerosis Study tri-
als. However, although the procedural complications may
have improved, the indications for carotid stenting and 
its efficacy remain undefined. In addition, there have been
new developments in carotid stenting, such as lower pro-
file systems, stents specifically designed for the carotid
artery, and embolic protection devices. If these advance-
ments do eventually improve the results and relative risk 
of carotid stenting, greater use for the procedure may 
be identified. 
Our previous experience at the University of Alabama
at Birmingham has identified a higher stroke rate in the
carotid stenting group when compared with our
endarterectomy experience.7,8 Subsequently, we have
sought to determine an appropriate subgroup in which to
apply this technique. Ouriel et al11 identified certain phys-
iologic factors (cardiac, renal, pulmonary dysfunction)
that were associated with a higher stroke and non-stroke
morbidity rate. In another report, Rothwell, Slattery, and
Warlow12 identified anatomic risk factors (contralateral
occlusion, carotid siphon stenosis, external carotid steno-
sis) that also impacted stroke rate. We believe that the
anatomic characteristics of the lesion (its location in the
neck and the nature of the surrounding tissue) can affect
the surgical morbidity rate more so than the physiologic
factors of the patient (cardiac dysfunction, etc). At pres-
ent, we recommend carotid stenting primarily for those
lesions that are surgically inaccessible rather than for
patients with poor physiologic risk factors. Yet “surgically
inaccessible” can be a relative term. We balance the physi-
ologic risk with the anatomic complexity for the determi-
nation of the surgical accessibility and then the best
treatment method. For example, the stenting of a proxi-
mal common carotid lesion may be preferable to a ster-
notomy and arch reconstruction in some patients. In our
Table III. Logistic regression analysis results of each high-risk procedure and each criterion
Outcome 3: 
Outcome 1: Outcome 2: either stroke/death or
stroke/death cardiac complication cardiac complication
% P value % P value % P value
Risk category Normal (n = 317) 1.89 .2443 0.95 .1581 2.84 .0705
High (n = 98) 4.08 3.06 7.14
Cardiac dysfunction No (n = 385) 2.34 .7448 0.78 .0043 3.12 .0235
Yes (n = 30) 3.33 10.00 13.3
Combined revascularization No (n = 402) 2.24 .3085 1.49 .5351 3.73 .5165
Yes (n = 14) 7.14 0.00 7.14
Pulmonary dysfunction No (n = 407) 2.46 .5301 1.47 .6276 3.93 .4254
Yes (n = 8) 0.00 0.00 0.00
Contralateral carotid No (n = 384) 2.34 .7685 1.56 .3326 3.91 .8460
occlusion Yes (n = 31) 3.23 0.00 3.23
Recurrent disease No (n = 390) 2.56 .2620 1.54 .3861 4.10 .1543
Yes (n = 25) 0.00 0.00 0.00
Anatomic limitations No (n = 411) 2.43 .6579 1.46 .7322 3.89 .5740
Yes (n = 4) 0.00 0.00 0.00
opinion, clinicians should proceed cautiously when using
carotid stenting solely because of physiologic risk factors.
We found in this analysis of our 415 procedures that the
physiologic risks were not associated with a higher stroke
risk but may have been associated with a slightly higher car-
diac risk. Specifically, 47 procedures were classified as high
risk because of the physiologic reasons of cardiac dysfunc-
tion, combined revascularization, or pulmonary dysfunc-
tion. The stroke rate was similar between these high (4.3%)
and low (2.2%) physiologic risk groups, but the cardiac
morbidity rate alone remains higher (6.4%) than the rate in
the low physiologic risk group (0.8%). Carotid stenting,
which might decrease cardiac morbidity rates in patients at
high risk, would need to maintain similarly low stroke rates
of CEA to be clinically effective for this group. In addition,
these patients at high risk can undergo a surgical procedure
with regional anesthesia with no effect on stroke risk rate
(2.3% versus 2.5%; Table IV) and no difference in cardiac
risk rate (1.9% versus 1.0%; Table IV). We have previously
reported that CEA with regional anesthesia has a stroke risk
rate as low as 0.9%.8 Subgroup analysis results in this series
show a slightly higher rate (2.5%), but we still believe that
CEA can be accomplished with regional anesthesia in those
patients who may seem to be at a high risk for general anes-
thesia. Furthermore, although this study was not specifically
designed for the evaluation of the effects of anesthetic tech-
nique, the results suggest that cardiac morbidity rates may
not be affected by the type of anesthesia but instead by the
patient’s inherent coronary artery disease.
In a comparison of our results with the results of other
reports, our combined stroke, death, and cardiac end point
rates are not as contrasting in the patients at high risk as the
results of some other reports.9 This difference may repre-
sent a smaller sample size in our series (n = 415) as com-
pared with the 3000 procedures reported by the Cleveland
Clinic. However, our investigation analyzed the most recent
3 years, which may make it more applicable to today’s pop-
ulation. In addition, our stroke rates compared favorably in
both the high-risk and low-risk groups and fell within the
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guidelines of the American Heart Association’s suggestion
of stroke rate of less than 3% for asymptomatic and of less
than 6% for symptomatic carotid occlusive disease.14
A recent report that compared carotid angioplasty
with CEA declared a similarity between these two thera-
pies.15 However, in the Carotid and Vertebral Artery
Transluminal Angioplasty Study series, surgical stroke and
death rates exceeded the stroke rate in this report (10.0%
versus 2.6%). Specifically, 75% of these four deaths in the
surgical arm of the CAVATAS report were related to non-
neurologic causes, and the single death in our series was
related to a cardiac cause (the patient died 9 days after a
second CEA that was complicated with an exacerbation of
congestive heart failure). With the consideration of the
sample sizes (253 surgical CAVATAS patients to 415
patients in this series), our lower death rate may be related
to a broader application of regional anesthesia (48% in this
series versus 7% in CAVATAS) in patients who had a high
physiologic risk. The cardiac morbidity rate was not sig-
nificantly different in a comparison of anesthetic types, but
our series was not randomized. Therefore, we cannot con-
clusively state that regional anesthesia has an impact on
cardiac morbidity rates, although we tended to use
regional anesthesia for the patient at high physiologic risk.
The primary weakness of carotid stenting may be the
embolization that occurs in the inflation of a balloon and in
the passing of devices through a diseased carotid bifurcation.
Microemboli have been shown to occur at a substantially
higher rate with carotid angioplasty when compared with
surgery,16 but because technologic advances have occurred,
various methods of embolic protection associated with this
procedure are becoming available. When the embolic load is
reduced, the stroke risk may also be reduced.17 Therefore,
the availability of embolic protection may broaden the appli-
cation of stenting. Currently, embolic reduction is under
investigation in carotid stenting trials with a distal embolic
capturing device for patients at high risk.
Finally, although carotid stenting is undergoing contin-
ued clinical trials and the Healthcare Finance Administration
Table IV. Additional risk factors analyzed with logistic regression analysis for effect on morbidity rate
Outcome 3: 
Outcome 1: Outcome 2: either stroke/death or
stroke/death cardiac complication cardiac complication
% P value % P value % P value
Anesthesia type General (n = 214) 2.34 .9201 1.87 .4510 4.21 .7018
Local (n = 201) 2.49 1.00 3.48
Sex Male (n = 288) 1.39 .0521 1.04 .3187 2.43 .0302
Female (n = 127) 4.72 2.36 7.09
CAD No (n = 197) 2.03 .6306 0.00 .0052 2.03 .0597
Yes (n = 218) 2.75 2.75 5.50
Preoperative symptoms Asymptomatic (n = 235) 1.28 .0853 1.70 .6127 2.98 .2919
Symptomatic (n = 180) 3.89 1.11 5.00
Age (as a continuous 1.406 .3314 1.265 .5988 1.358 .2716
variable)
CAD, Coronary artery disease.
has limited reimbursement to only those protocols that are
undergoing clinical trials,18 we continue to pursue carotid
stenting for anatomically inaccessible lesions. Specifically, we
believe that the experienced carotid surgeon can make a bet-
ter judgment about the technical aspects of carotid recon-
struction as compared with an angiographer alone. Although
the medical condition of the patient is an important consid-
eration for any surgical therapy, the physiologic stress of CEA
is quite low with a total stroke, death, and cardiac complica-
tion rate of 3.9%. Continued evaluation of carotid stenting
should be undertaken in a carefully controlled clinical setting
in which multiple disciplines should consider both the
anatomic and physiologic risks of the patient.
This retrospective analysis has some limitations.
Specifically, there was not an independent neurologist for
the examination of all the patients. However, we found lit-
tle difficulty in the identification of a neurologic deficit
after a carotid procedure. The differentiation was more
challenging in the consideration of the duration of the dis-
ability and, therefore, the classification of a TIA. Three
patients had TIAs but had no persistent neurologic deficit
beyond 24 hours and no radiographic evidence of stroke.
An independent neurologist evaluated all of these patients
with TIAs. In addition, the study size may have limited our
ability to determine a real difference in these subgroups.
Instead, 3200 patients would be required for the determi-
nation of a definite statistical difference between 2% and 4%
in low-risk and high-risk groups. From a different perspec-
tive, a sample size of 400 would be needed for the defini-
tion of a difference of 10% stroke, death, or cardiac event
rate in the high-risk group to have 80% probability of a dif-
ference in these two groups. Thus, our sample size and rel-
atively low morbidity rates in both groups make the
possibility of a real difference in stroke rates small. For a
significant difference in future comparisons of CEA and
carotid stenting, a large sample size will be required to
avoid an apparent non-difference between the two thera-
pies. However, smaller sample sizes can be sufficient if dra-
matic differences in the treatment methods are present.5
CONCLUSION
CEA can be undertaken in patients at high risk with
acceptable stroke rates that are similar to the rates of
patients at low risk. In a consideration of cardiac compli-
cations of MI, congestive heart failure, and atrial fibrilla-
tion along with all strokes and death, the total morbidity
rate may be increased in the high-risk group. The current
clinical application for carotid stenting should be limited
to anatomically difficult lesions as determined by an expe-
rienced carotid surgeon. Otherwise, we maintain that the
evaluation of carotid stenting should be done in carefully
controlled clinical trials until further clinical evidence
avails itself.
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Dr Kenneth Ouriel (Cleveland, Ohio). It’s my pleasure to
discuss this work of Dr Jordan’s and his group, work that was
directed at identifying a subset of carotid endarterectomy patients
that are at higher than usual risk for complications.
As vascular surgeons, we know carotid endarterectomy to be
one of our safest procedures. The rate of perioperative complica-
tions is lower than almost any peripheral vascular procedure, and
the long-term durability of endarterectomy is extraordinary.
Herein lies the challenge for carotid stenting. To compete
successfully against endarterectomy, stenting will need to be nearly
equivalent with regard to stroke and death. Given the insecurities
associated with this newer modality, we, as well as the UAB group,
identified a high-risk subpopulation for whom stenting might be
appropriate. This subgroup comprised just under one fourth of
the UAB patients. Although the stroke rate was similar in the
high- and low-risk groups, there were trends toward a higher rate
of perioperative complications in the high-risk subset.
I have just two questions for the authors.
First, given the relatively small sample size of this study, what
is their feeling about the risk of a true difference in stroke or
death being missed due to low power and a high probability of a
Type II error?
And second, what is their view on performing any procedure,
be it endarterectomy or stent, in a population with multiple med-
ical comorbidities? Carotid endarterectomy has been shown to be
of benefit in a relatively low-risk population with a considerable
life expectancy. Are the prospects for long-term survival poor
enough in this high-risk group that patients will not live long
enough to pay off the debt of periprocedural complications?
Dr William D. Jordan, Jr. I think you’re absolutely correct in
that one can examine the power that we have in the study. It was
only 400 cases. And compared to the 3000 that were reported
from Cleveland Clinic, our series is small.
We actually asked our statistician to evaluate that problem.
He found that if there is a difference of 2% to 4%, which is
roughly what we had, our sample size would need to be 3200
patients. That’s going to take us a few more years in Birmingham
to get that total.
We also looked at it from another perspective: what would
the difference need to be with this small subset of patients? With
only 400 patients, the difference would need to be 2% versus 10%
in one group or the other.
I call your attention specifically to the Wallstent trial, because
that randomized trial did have a difference, it was actually 4% ver-
sus 12% in that group. That trial was interrupted before its com-
pletion after a futility analysis. This trial abstract was presented in
February 2001.
Your next point about those patients who have a limited life
expectancy. We tend to be less aggressive for the asymptomatic
patient who has a limited life expectancy. Specifically, we want to
see at least 2 years before we operate on the asymptomatic
patient. I think that when you truly find those who are sympto-
matic, we get a lot more aggressive. We tend to be less aggressive
for the asymptomatic patient, and I think many patients are then
treated medically.
Dr Peter R. F. Bell (Leicester, United Kingdom). Could I ask
you one question?
There have now been three randomized trials: Our own in
Leicester; the one you just quoted, with a 12.1% complication
rate; and the CAVATAS trial which recently reported in Lancet 2
weeks ago with a 10% stroke rate following stenting. You said at
the end of your last slide that we should do randomized studies.
I have a problem with that. And the problem I have is how do you
get informed consent from the patient when your stroke rate and
death rate is 2%, as ours is? How do I tell a patient we should do
a trial? Could you explain that to me, please?
Dr Jordan. That issue is very important. My enthusiasm for
randomization is still very quieted until the embolization problem
is improved.
I’m specifically looking for embolic protection, via various
means. I’m aware of the CAVATAS data and some report the
stroke rate at 6%, but other reports have said 10%. At this point,
because we still are seeking distal protection, I use carotid stent-
ing for those who have surgically inaccessible lesions. As distal
protection becomes more available and those data become avail-
able, I will then have more enthusiasm for enrolling patients in
trials.
Dr Hero Van Urk (Rotterdam, The Netherlands). Since car-
diac complications are a large proportion of your postoperative
morbidity, I wonder whether you used beta blockers in your
patients with a high cardiac risk, since we have shown that the use
of beta blockers results in a tenfold decrease of postoperative car-
diac morbidity.
And the second question is, did you use stress echocardiog-
raphy or any other procedure like that to stratify your cardiac risk
patients?
Dr Jordan. We did not do stress testing for patients in terms
of a cardiac evaluation. We usually would not undertake cardiac
evaluation unless they had a suspicious clinical history, because we
feel that the physiologic risks of a carotid procedure are quite low.
Your next question regarding beta blockade, we did not rou-
tinely use beta blockade. Since your publication, we’ve become
more liberal with the use of beta blockers but did not specifically
apply their use to this entire group.
Dr Geun Eun B. Kim (Seoul, South Korea). I’d like to know
whether in your criteria for high-risk patients for stenting, did you
consider plaque characteristic, such as B-mode finding of echolu-
cent plaque? As we have reported previously, patients with the
echolucent plaque are more symptomatic, and these patients may
be more prone to embolization during the stenting.
Dr Jordan. No, we did not specifically separate our results
based upon the duplex findings.
DISCUSSION
